Movement Alert｜Novartis Rises 3.01% in Regular Trading, Antibody-Conjugated Oligonucleotide Drug Delivers Positive Early Clinical Data

Market Focus06-24

On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.

On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug del-brax achieved the primary endpoint and key secondary endpoints in a Phase 1/2 study, demonstrating robust target engagement and reduced muscle damage in patients with facioscapulohumeral muscular dystrophy. Del-brax is one of three potential first-in-class therapies Novartis acquired, with the other two targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy respectively. The positive readout reinforces Novartis's strategic expansion into rare neuromuscular diseases through its acquisition pipeline.

Within the Pharmacy sector where Novartis belongs, the broader sector showed strength. Among individual stocks, Johnson & Johnson up 3.44%, Merck up 3.55%, Novo-Nordisk up 3.33%, Eli Lilly up 0.65%, Pfizer down 1.44%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159331467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159331467","market":"us","top_or_hot":-1,"title":"Movement Alert｜Novartis Rises 3.01% in Regular Trading, Antibody-Conjugated Oligonucleotide Drug Delivers Positive Early Clinical Data","media":"Market Focus","content":"<p><p>On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.</p><p>On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug del-brax achieved the primary endpoint and key secondary endpoints in a Phase 1/2 study, demonstrating robust target engagement and reduced muscle damage in patients with facioscapulohumeral muscular dystrophy. Del-brax is one of three potential first-in-class therapies Novartis acquired, with the other two targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy respectively. The positive readout reinforces Novartis's strategic expansion into rare neuromuscular diseases through its acquisition pipeline.</p><p>Within the Pharmacy sector where Novartis belongs, the broader sector showed strength. Among individual stocks, Johnson & Johnson up 3.44%, Merck up 3.55%, Novo-Nordisk up 3.33%, Eli Lilly up 0.65%, Pfizer down 1.44%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novartis Rises 3.01% in Regular Trading, Antibody-Conjugated Oligonucleotide Drug Delivers Positive Early Clinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novartis Rises 3.01% in Regular Trading, Antibody-Conjugated Oligonucleotide Drug Delivers Positive Early Clinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.</p><p>On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug del-brax achieved the primary endpoint and key secondary endpoints in a Phase 1/2 study, demonstrating robust target engagement and reduced muscle damage in patients with facioscapulohumeral muscular dystrophy. Del-brax is one of three potential first-in-class therapies Novartis acquired, with the other two targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy respectively. The positive readout reinforces Novartis's strategic expansion into rare neuromuscular diseases through its acquisition pipeline.</p><p>Within the Pharmacy sector where Novartis belongs, the broader sector showed strength. Among individual stocks, Johnson & Johnson up 3.44%, Merck up 3.55%, Novo-Nordisk up 3.33%, Eli Lilly up 0.65%, Pfizer down 1.44%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"","article_id":"1159331467","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159331467","pubTimestamp":1782244804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"动静快讯|诺华常规交易涨3.01%抗体偶联寡核苷酸药物交付积极早期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug del-brax achieved the primary endpoint and key secondary endpoints in a Phase 1/2 study, demonstrating robust target engagement and reduced muscle damage in patients with facioscapulohumeral muscular dystrophy. Del-brax is one of three potential first-in-class therapies Novartis acquired, with the other two targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy respectively. The positive readout reinforces Novartis's strategic expansion into rare neuromuscular diseases through its acquisition pipeline.Within the Pharmacy sector where Novartis belongs, the broader sector showed strength. Among individual stocks, Johnson & Johnson up 3.44%, Merck up 3.55%, Novo-Nordisk up 3.33%, Eli Lilly up 0.65%, Pfizer down 1.44%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159331467","isCrawlerRequest":true}